Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Cox, M Christina ^a   Di Napoli, Arianna ^a   Scarpino, Stefania ^a   Salerno, Gerardo ^a   Tatarelli, Caterina ^a   Talerico, Caterina ^a   Lombardi, Mariangela ^a   Monarca, Bruno ^a   Amadori, Sergio ^b   Ruco, Luigi ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M; LENALIDOMIDE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; BCL6 PROTEIN, HUMAN; DNA BINDING PROTEIN; MONOCLONAL ANTIBODY; MYC PROTEIN; MYC PROTEIN, HUMAN; PROTEIN BCL 2; R-CHOP PROTOCOL;

ADULT; ARTICLE; BCL2 GENE; BCL6 GENE; BONE MARROW; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; EVENT FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; IMMUNOBLAST; IMMUNOGLOBULIN BLOOD LEVEL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYD88 GENE; ONCOGENE; ONCOGENE MYC; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TUMOR CELL; IMMUNOLOGY; ITALY; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DNA-BINDING PROTEINS; DOXORUBICIN; HUMANS; IMMUNOGLOBULIN M; IN SITU HYBRIDIZATION, FLUORESCENCE; ITALY; LYMPHOMA, LARGE B-CELL, DIFFUSE; PREDNISONE; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 84899451802     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093903     Document Type: Article

References (54)

1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, et al. (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117: 5019-32.
2. Fu K, Weisenburger DD, Choi WW, Perry KD, Smith LM, et al. (2008) Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2628: 4587-94.
3. Sehn LH, DJ, Chanabhai M, Fitzgerald C, Gill K, Klasa R, et al. (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J ClinOncol 23: 5027-5033.
4. Project, TIN-HsLPF (1993) A predictive model for aggressive non-Hodgkin's lymphoma The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329: 987-994.
5. Alizadeh AA, Davis EM, Ma RE, Lossos C, Rosenwald A, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 3; 403: 503-511. (Pubitemid 30082188)
6. Visco C, LY, Xu Monette ZY, Miranda RN, Green TM, Li Y, et al. (2012) Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 269: 2103-2113.
7. Advani RH, Habermann CH, Morrison TM, Weller VA, Fisher EA, et al. (2010) Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study ECOG 4494, CALGB 9793: consideration of age greater than 70 years in an elderly prognostic index E-IPI. Br J Haematol 1512: 143-151.
8. Cox MC, Nofroni I, Ruco L, Amodeo R, Ferrari A, et al. (2008) Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell- lymphoma. Leuk Lymphoma 499:1745-51.
9. Barrans S, Crouch S, Smith A, Turner K, Owen R, et al. (2010) Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab J Clin Oncol 2820: 3360-65.
10. Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, et al. (2012) Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. J Clin Oncol 3028: 3460-7
11. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, et al. (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 3028: 3452-59.
12. Horn H, Becher ZM, Barth C, Bernd TF, Feller HW, et al. (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121: 2253-63.
13. Noguchi M, Yamazaki S, Suda K, Sato N, Oshimi K, et al. (2003) Multifocal motor neuropathy caused by a B-cell lymphoma producing a monoclonal IgM autoantibody against peripheral nerve myelin glycolipids GM1 and GD2b. Br J Haematol 1234: 600-605. (Pubitemid 37468055)
14. Lin P, Hao S, Handy BC, Bueso-Ramos CE, Medeiros J, et al. (2005) Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients Am J Clin Pathol 1232: 200-205. (Pubitemid 40194080)
15. Eskazan AE, Akmurad H, Ongoren S, Ozer O, Ferhanoglu B (2011). Primary gastrointestinal diffuse large B cell lymphoma presenting with cold agglutinin disease. Case Rep Gastroenterol 52: 262-266.
16. Maurer MJ, Micallef INM, Cerhan JR, Katzmann JA, Link BK, et al. (2011) Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol 2912: 1620-1626.
17. Jardin F, Molina TJ, Copie Bergman C, Brièr J, Petrella T, et al. (2013) Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma. Leuk Lymphoma 54:1898-907.
18. Cox MC, Di Napoli A, Scarpino S, Cavalieri E, Naso V, et al. (2012) Diffuse-Large-B-Cell Lymphoma Patients With Secreting IgM Monoclonal Component is A Very Poor Prognostic Subset. Blood 120: 2659
19. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, et al. (2008) WHO classification of Tumors of Haematopoietic and lymphoid Tissues. IARC press, Lyon.
20. Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, et al. (2004). Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104: 626-33. (Pubitemid 38970553)
21. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, et al. (2007) Italian Association for the Study of the Liver. Prophylaxis and treatment of hepatitis B in mmunocompromised patients. Dig Liver Dis 39: 397-408. (Pubitemid 46508732)
22. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, et al. (2004). Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275-82. (Pubitemid 38029949)
23. Ventura RA, Martin-Subero JI, Jones M, McParland J, Gesk S, et al. (2006) FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn 82:141-51. (Pubitemid 43811236)
24. Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, et al. (2013) Monoclonal gammopathy, and other B-cell lymphoproliferativeMYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 121: 2051-58.
25. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, et al. (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 255: 579-86. (Pubitemid 350002966)
26. Kaplan EL (1958) Meier P Non-parametric estimation from incomplete observations J Am Stat Assoc 53: 457-81.
27. Cox D (1972) Regression models and life tables. J R Stat Assoc 34: 187-220.
28. Choi JW, Kim Y, Lee JH, Kim YS (2013) MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. Hum Pathol 44: 1375-81.
29. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, et al. (2012) Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma DLBCL by whole-exome sequencing. Proc Natl Acad Sci U S A 10910: 3879-84.
30. Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJ, Oud ME, et al. (2013) High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J doi: 10.1038/bcj.2013.28.
31. Zinzani PL, PC, Merla E, Ballerini F, Fabbri A, Guarini A, et al. (2012) Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicentre retrospective study. Hematological Oncology, in press.
32. Rigacci L, Vitolo U, Cox MC, Devizzi L, Fabbri A, et al. (2012) Lenalidomide Is Effective in Heavily Pretreated Non Hodgkin Lymphoma NHL: Analysis of a Retrospective Data Collection. Blood 120: 3694.
33. Vitolo U, Angelucci E, Rossi G, Liberati AM, Cabras MG, et al. (2009) Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica 949: 1250-1258.
34. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, et al. (2011). Oncogenically active MYD88 mutations in human lymphoma. Nature 470:115-9.
35. Randen U, Trøen G, Tierens A, Steen C, Warsame A, et al. (2014) Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica 99: 497-504.
36. Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, et al. (1998) Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92: 3152-3162. (Pubitemid 28492322)
37. Copie-Bergman C, Gaulard P, Leroy K, Briere J, Baia M, et al. (2009) Immunofluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA Study. J Clin Oncol 27: 5573-5579.
38. Barrans SL, Evans PA, O'Connor SJ, Kendall SJ, Owen RG, et al. (2003) The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res 9: 2133-2139. (Pubitemid 36687635)
39. Akyurek N, Uner A, Benekli M, Barista I (2012) Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 118: 4173-83.
40. Pedersen MO, Gang AO, Poulsen TS, Knudsen H, Lauritzen AF, et al. (2014) MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations. Eur J Haematol 92: 42-8.
41. Lenz G, Siebert R, Roschke AV, Sanger W, Wright GW, et al. (2007) Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med 2043: 633-643. (Pubitemid 46457085)
42. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, et al. (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 100: 9991-9996. (Pubitemid 37087056)
43. Ruminy P, Couronné L, Parmentier F, Rainville V, Mareschal S, et al. (2011) The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma Leukemia 254: 681-688.
44. Montes-Moreno S, Rodriguez Pinilla MA, Maestre SM, Sanchez Verde L, Roncador G, et al. (2010) Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica 958: 1342-1349.
45. Hoeller S, Tzankov A, Pileri SA, Went P, Dirnhofer S, et al. (2010) Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol 41:352-357.
46. Ahn JS, Yang DH, Duk Choi Y, Jung SH, Yhim HY, et al. (2013) Clinical outcome of elderly patients with Epstein-Barr virus positive diffuse large B-cell lymphoma treated with a combination of rituximab and CHOP chemotherapy. Am J Hematol 88:774-9.
47. Lennert K, Feller A (1992) Histopathology of Non-Hodgkin's Lymphomas. New York: Springer Verlag.
48. Ott G, Ziepert M, Klapper W, Horn H, Szczepanowski M, et al. (2010) Immunoblastic morphology but not the immunohistochemical GCB/non-GCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 116: 4916-25.
49. Kohyama S, NH, Shima K, Shimazaki H (2001) Primary central nervous system lymphoma with paraproteinemia. Surg Neurol 565: 325-328.
50. Montesinos-Rongen M, Courts SR, Stenzel CW, Bechtel D, Niedobitek G, et al. (2005) Absence of immunoglobulin class switch in primary lymphomas of the central nervous system. Am J Pathol 1666:1773-9. (Pubitemid 40734400)
51. Ria R, Occhiogrosso G, Ciappetta P, Ribatti D, Vacca A, et al. (2009) Monoclonal gammopathy as a marker of primary cerebral lymphoma. Eur J Clin Invest 397: 627-629.
52. Schroers R, Baraniskin A, Heute C, Kuhnhenn J, Alekseyev A, et al. (2010) Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas. Eur J Haematol 853:236-242.
53. Martelli M, Ferreri A, Agostinelli C, Di Rocco A, Pfreundschuh M, et al. (2013) Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 87:146-71.
54. Koens L, Willemze R, Jansen PM (2010) IgM expression on paraffin sections distinguishes primary cutaneous large B-cell lymphoma, leg type from primary cutaneous follicle center lymphoma. Am J Surg Pathol 347: 1043-1048.